Cannabinoid Overview

Course #68010-


Self-Assessment Questions

    1 . What legislation is responsible for making hemp and its constituents, including cannabidiol (CBD), legal for sale?
    A) Controlled Substances Act (CSA)
    B) Domestic Hemp Production Program Act of 2019
    C) Agriculture Improvement Act of 2018
    D) Dietary Supplement and Health Education Act (DSHEA)

    THE AGRICULTURE IMPROVEMENT ACT OF 2018

    In 2018, the Agriculture Improvement Act, also known as the Farm Bill, completely changed the landscape for the sale of cannabinoid products in the United States. This new bill defines hemp as Cannabis sativa and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a THC concentration of not more than 0.3% on a dry weight basis. According to the Farm Bill, cannabis (or what we commonly refer to as marijuana) is considered Cannabis sativa containing more than 0.3% THC. The Farm Bill made hemp and its constituents, including CBD, exempt from the Controlled Substances Act and legal for sale [1,2].

    Click to Review



    2 . Nabiximols, a prescription oromucosal spray containing whole-plant cannabis extract (Sativex), delivers what dose of THC/CBD with each spray?
    A) THC 0.27 mg and CBD 0.25 mg
    B) THC 2.7 mg and CBD 2.5 mg
    C) THC 27 mg and CBD 25 mg
    D) THC 270 mg and CBD 250 mg

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    While it is unclear if smoking cannabis improves multiple sclerosis-related symptoms, a prescription product available in Canada and most of Europe, as well as other products containing the combination of THC and CBD, seem to reduce spasticity in patients with multiple sclerosis. Nabiximols, a prescription oromucosal spray containing whole-plant cannabis extract (Sativex), is available in most of Europe and Canada but is not yet approved in the United States. Each actuation of this cannabis extract spray is standardized to deliver THC 2.7 mg and CBD 2.5 mg [1].

    Click to Review



    3 . Which of the following statements regarding Cannabis use during pregnancy and lactation is TRUE?
    A) Cannabis does not cross the placenta.
    B) THC in breast milk is not correlated with effects in the infant.
    C) THC is excreted into the breast milk for no more than two weeks following cessation of use.
    D) Cannabis use during pregnancy has been associated with numerous negative maternal and fetal outcomes in observational studies.

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    Cannabis crosses the placenta, and use during pregnancy has been associated with numerous negative maternal and fetal outcomes in observational studies. THC is excreted into the breast milk for at least six weeks following cessation of use and can cause delayed motor development in the infant [1]. Patients should be informed of these risks and discouraged from using cannabis while pregnant or breastfeeding.

    Click to Review



    4 . What is the prescription formulation of CBD approved to be used for?
    A) Monotherapy for Sturge-Weber syndrome and febrile infection-related epilepsy syndrome (FIRES)
    B) Adjunctive therapy for Sturge-Weber syndrome and febrile infection-related epilepsy syndrome (FIRES)
    C) Monotherapy for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex
    D) Adjunctive treatment for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    A prescription CBD solution approved by the FDA is labeled for the adjunctive treatment of Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Prescription CBD is an oil-based oral solution standardized to contain CBD extract 100 mg/mL in sesame oil. The extract is highly purified from a plant source. Originally classified by the DEA as a Schedule V controlled substance, it was descheduled in April 2020 [3].

    Click to Review



    5 . What can be said about the available data for the use of CBD for mental health?
    A) In patients diagnosed with anxiety, CBD improves anxiety symptoms and the ability to cope with stress.
    B) In patients diagnosed with social anxiety disorder, CBD consistently reduces anxiety during the speaking event.
    C) In patients diagnosed with depression, CBD research is inconclusive for showing any symptom improvement.
    D) In patients diagnosed with post-traumatic stress disorder (PTSD), CBD improves alertness and discomfort.

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    Research on the use of CBD for mental health benefits is inconclusive. In healthy patients, several small, low-quality studies show that oral CBD 15 mg or 150 mg modestly improves emotional exhaustion, depression or anxiety symptoms, and the ability to cope with stress, when compared with standard care or placebo, but it is not clear if CBD is beneficial in patients diagnosed with anxiety or depression [3].

    Click to Review



    6 . Cannabidivarin
    A) is structurally similar to THC.
    B) is a psychoactive cannabinoid with structural similarity to CBD.
    C) seems to act through many of the same receptor pathways as CBD.
    D) occurs in lower concentrations in Cannabis indica than in Cannabis sativa.

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    Cannabidivarin is a nonpsychoactive cannabinoid with structural similarity to CBD. The concentration of cannabidivarin is greater in Cannabis indica than in Cannabis sativa. While cannabidivarin is structurally similar to CBD, it is the biosynthetic precursor to tetrahydrocannabivarin, which results from the isomerization of cannabidivarin under acidic conditions. Based on the available laboratory and animal research, it seems to act through many of the same receptor pathways as CBD [4].

    Click to Review



    7 . Which of the following cannabinoids seems to reverse the antiemetic effects of CBD when used concomitantly?
    A) Cannabidiol
    B) Cannabigerol
    C) Cannabidivarin
    D) Cannabichromene

    REVIEWING THE EVIDENCE: EFFICACY AND SAFETY

    Although there is interest in using cannabigerol for conditions such as cachexia, dyslipidemia, Huntington disease, and inflammatory bowel disease, available research is limited to in vitro and animal studies. Some research shows that the anti-inflammatory effects of cannabigerol might be greater when used in combination with CBD, but cannabigerol also seems to reverse the antiemetic effects of CBD when used concomitantly [7].

    Click to Review



    8 . Which of the following is among the most common adverse effects associated with delta-8 THC?
    A) Psychosis
    B) Depressed mood
    C) Respiratory depression
    D) Difficulty thinking and speaking

    GENERAL SAFETY CONSIDERATIONS

    According to data compiled from sources including the FDA, the Centers for Disease Control and Prevention (CDC), and the American Association of Poison Control Centers, some of the most common adverse effects associated with delta-8 THC include difficulty thinking and speaking, a dreamlike state, euphoria, feeling "high," and vision and time distortion. Serious safety signals also have been observed, including Brugada ECG pattern and cannabinoid hyperemesis syndrome, frequently leading to emergency room visits and hospitalization [9].

    Click to Review



    9 . How is cannabinoid hyperemesis syndrome (CHS) treated?
    A) Cold showers
    B) Ondansetron
    C) Lower doses of cannabis more often
    D) Complete discontinuation of cannabis use

    GENERAL SAFETY CONSIDERATIONS

    The cornerstone of long-term treatment for CHS is complete discontinuation of cannabis use, but benzodiazepines and capsaicin also may play a role in short-term symptom management [10].

    Click to Review



    10 . Which cannabinoid dosage form has resulted in a recent uptick in accidental exposures in children?
    A) Edibles
    B) Essential oils
    C) Oral pills
    D) Topicals

    GENERAL SAFETY CONSIDERATIONS

    There has been a recent uptick in accidental ingestion of cannabis-containing edibles in children ages 12 years and younger. Legalization of recreational cannabis and the availability of these more appealing food forms, like gummies, are likely to blame. Accidental ingestion of cannabis-containing edibles in children has been associated with ataxia, coma, hypotonia, hypothermia, lethargy, nystagmus, respiratory depression, seizures, and tremors [1].

    Click to Review